Diagnosis and Management of Polycythemia Vera

Diagnostic Criteria

• The diagnosis of polycythemia vera (PV) requires meeting specific criteria that include laboratory evidence of increased red blood cells and JAK2 mutation testing, with additional minor criteria to confirm the diagnosis when needed 1
• Diagnosis requires either: both major criteria AND at least one minor criterion, OR first major criterion AND at least two minor criteria 1
• A comprehensive diagnostic workup, including complete blood count with MCV, reticulocyte count, serum ferritin, transferrin saturation, and CRP, is essential to determine the underlying cause of polycythemia and macrocytosis, as recommended by the National Comprehensive Cancer Network and the American Journal of Kidney Diseases 2, 3, 4
• Initial suspicion of PV should be raised when hemoglobin/hematocrit is above the 95th percentile adjusted for sex and race, or when there is a documented increase in hemoglobin/hematocrit above the patient's baseline, as recommended by the American Society of Hematology 5, 1
• Erythrocytosis is defined as a hematocrit level >51% or hemoglobin level >17 g/dL (170 g/L), with normal adult hematocrit values being 47 ± 6% for males and 41 ± 5% for menstruating females, as per the American Journal of Kidney Diseases guidelines 3, 4
• The following table summarizes the types of secondary polycythemia:

• Serum erythropoietin level measurement can help distinguish primary from secondary polycythemia, with low levels suggesting primary polycythemia (polycythemia vera) and normal/elevated levels suggesting secondary causes 5
• JAK2 V617F mutation testing has a sensitivity of >95% for polycythemia vera, and if JAK2 is negative but strong clinical suspicion remains, testing for JAK2 exon 12 mutation is recommended by the National Comprehensive Cancer Network 6
• Bone marrow biopsy can assess for hypercellularity with trilineage growth and evaluate for other myeloproliferative features, as recommended by the National Comprehensive Cancer Network 6

Treatment and Management

• Therapeutic phlebotomy is recommended to maintain hematocrit <45% in men (and corresponding values for women) as first-line therapy for all patients with polycythemia vera, as recommended by the American College of Physicians 5
• Low-dose aspirin (81-100 mg daily) is recommended to reduce the risk of thrombotic complications, unless contraindicated due to extreme thrombocytosis (>1,500 × 10⁹/L), as recommended by the European LeukemiaNet and the American Society of Hematology 7, 8, 4, 5, 9, 1
• Hydroxyurea is recommended as a first-line cytoreductive therapy for patients with splenomegalia, with an initial dose of 15-20 mg/kg/day and adjustment to maintain leukocytes >2,500/μL and platelets >100,000/μL, as recommended by the National Comprehensive Cancer Network 7, 8
• Interferon-alfa is an alternative first-line therapy, particularly in younger patients, as it has no known leukemogenic potential and can reduce the JAK2V617F allele burden, as recommended by the European LeukemiaNet and the National Comprehensive Cancer Network 7, 8

Monitoring and Follow-up

• Regular monitoring of hematological parameters, including CBC every 2-3 months initially and then every 3-6 months if stable, is recommended to assess for disease progression, thrombotic and bleeding complications, as stated by the American Society of Hematology and the National Comprehensive Cancer Network 4, 5, 9, 10, 1, 7
• Periodic evaluation of spleen size and monitoring for symptoms of hyperviscosity are essential, as recommended by the European LeukemiaNet 7
• Aggressive control of cardiovascular risk factors, including smoking cessation, is crucial in patients with polycythemia vera, as recommended by the European LeukemiaNet and the American Society of Hematology 7, 4

Potential Pitfalls and Complications

• Overlooking other causes of chest pain, such as aortic dissection, pulmonary embolism, or pericarditis, can lead to delayed diagnosis and treatment, as warned by the European Society of Cardiology 11, 12
• Delaying cytoreductive therapy in high-risk patients can increase the risk of thrombotic complications, as cautioned by the American Society of Clinical Oncology 9
• Repetitive phlebotomies can deplete iron stores, resulting in iron-deficient red blood cells with reduced oxygen-carrying capacity and increased stroke risk in patients with polycythemia vera, as noted by the American College of Physicians and the American Heart Association 5, 13